Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume – Should You Buy?

Posted by Hanz Christensen on Apr 2nd, 2026

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) saw strong trading volume on Thursday . 281,087 shares were traded during mid-day trading, an increase of 294% from the previous session’s volume of 71,377 shares.The stock last traded at $12.51 and had previously closed at $12.7250.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on FSNUY. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

Get Our Latest Research Report on FSNUY

Fresenius SE & Co. Stock Down 1.6%

The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 0.99. The company has a fifty day moving average price of $14.13 and a 200 day moving average price of $14.36. The company has a market cap of $28.20 billion, a PE ratio of 19.87 and a beta of 0.75.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. The business had revenue of $6.94 billion for the quarter. As a group, analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.